INVO Fertility Enters $15M–$50M Dilutive Equity Line, Authorizes 5x Share Increase Amid Going-Concern Crisis
IVF is trading near its 52-week low of $1 (0.0% above the low).
Summary
INVO Fertility secured a $15M–$50M dilutive equity line with Alumni Capital LP, priced at a discount to market, and stockholders approved a 5x increase in authorized shares to 250M. The moves come as the company battles a going-concern warning and a stock price at its 52-week low.
Key Events · Financing and Capital Events · IVF
-
Dilutive Equity Line Signed
Entered into an Any Market Purchase Agreement with Alumni Capital LP for up to $15M (expandable to $50M) in common stock sales at discounts of 6%–15% off recent market prices, with the company controlling timing and amount of draws.
-
Authorized Shares Increased 5x
Stockholders approved an amendment to increase authorized common shares from 50M to 250M, and the company filed the Certificate of Amendment on July 23, 2026, providing headroom for massive dilution.
-
Pre-Approved Future Dilution
Stockholders separately approved a proposal allowing the company to issue 20% or more of outstanding common stock in a future equity financing at prices below market, further enabling deeply discounted capital raises.
-
Commitment Fee Adds to Dilution
The company must pay Alumni Capital a 1% commitment fee ($150K–$500K) in cash or shares, with additional fees if the commitment is increased, adding immediate dilution or cash outflow.
Analysis · IVF · Industrial Applications And Services
Already grappling with a going-concern warning and the threat of Nasdaq delisting, INVO Fertility has secured an equity line of credit with Alumni Capital LP that permits the sale of up to $15 million—and potentially $50 million—of common stock at discounts ranging from 6% to 15% off recent market prices. At the same time, stockholders approved a 5x increase in authorized shares to 250 million and separately greenlit a future equity financing that could issue 20% or more of the company at below-market prices. The convergence of a deeply discounted equity line, a massive authorized share expansion, and pre-approved dilutive financing signals extreme financial distress and a high likelihood of severe shareholder dilution. With the stock trading at its 52-week low of $1.00 and a market cap of only ~$1.8 million, even the initial $15 million commitment could result in overwhelming dilution if drawn.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 41.1% of the 372 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IVF was trading at $1.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.8M. The 52-week trading range was $1.00 to $102.40. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.